# Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

> **NCT02047214** · PHASE2 · TERMINATED · sponsor: **Cortice Biosciences, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** TPI 287
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02047214
- **Lead sponsor:** Cortice Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Due to lack of clinical benefit in the 17 subjects enrolled in the trial to date
- **Last updated:** 2018-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047214, "Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02047214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*